LifeVantage Corp (NASDAQ:LFVN) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 634,700 shares, a decline of 19.3% from the June 30th total of 786,800 shares. Currently, 4.8% of the shares of the company are sold short. Based on an average daily volume of 118,900 shares, the days-to-cover ratio is currently 5.3 days.

A number of institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN boosted its holdings in LifeVantage by 24.7% in the second quarter. Wells Fargo & Company MN now owns 17,302 shares of the company’s stock worth $224,000 after purchasing an additional 3,422 shares during the period. Two Sigma Advisers LP boosted its holdings in LifeVantage by 35.9% in the fourth quarter. Two Sigma Advisers LP now owns 14,372 shares of the company’s stock worth $190,000 after purchasing an additional 3,800 shares during the period. BlackRock Inc. boosted its holdings in LifeVantage by 1.8% in the fourth quarter. BlackRock Inc. now owns 242,383 shares of the company’s stock worth $3,197,000 after purchasing an additional 4,223 shares during the period. O Shaughnessy Asset Management LLC boosted its holdings in LifeVantage by 10.1% in the first quarter. O Shaughnessy Asset Management LLC now owns 51,497 shares of the company’s stock worth $736,000 after purchasing an additional 4,721 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its holdings in LifeVantage by 19.2% in the second quarter. Parametric Portfolio Associates LLC now owns 30,284 shares of the company’s stock worth $393,000 after purchasing an additional 4,881 shares during the period. 38.24% of the stock is owned by hedge funds and other institutional investors.

LifeVantage stock traded up $1.36 during mid-day trading on Thursday, reaching $12.48. The company’s stock had a trading volume of 248,142 shares, compared to its average volume of 126,045. The firm has a market cap of $155.12 million, a price-to-earnings ratio of 24.47 and a beta of 0.66. The business has a 50 day moving average price of $11.69 and a 200-day moving average price of $12.70. LifeVantage has a twelve month low of $9.75 and a twelve month high of $17.08.

Separately, ValuEngine downgraded shares of LifeVantage from a “buy” rating to a “hold” rating in a report on Thursday, August 1st.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.

See Also: What is a Stop Order?

Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.